# *6th isirv-AVG Conference*
# ***Advances in Respiratory Virus Therapeutics***

## Tuesday 13th - Thursday 15th November 2018
## Hilton Washington DC/ Rockville Hotel, Washington DC, USA

### Preliminary Programme

| | |
|---|---|
| **Tuesday 13 November** | |
| **08:30-08:45** | **Welcome & Opening** |
| **08:45-09:30** | **Session 1:** Keynote Lecture: BARDA Perspectives on Advancing Respiratory Virus Therapeutics<br>*Rick Bright, BARDA, Washington, D.C., USA* |
| **09:30-11:00** | **Session 2 :** Symposium - Preclinical Topics<br><br>Eritoran, a TLR 4 Antagonist<br>*Stefanie Vogel, University of Maryland, Baltimore, MD, USA*<br><br>Repurposing of drugs as novel influenza (and other respiratory viruses) inhibitors from clinical gene expression infection signatures<br>*Andres Pizzorno, Centre International de Recherche en Infectiologie (CIRI-Team VirPath) & Signia Therapeutics, Lyon, France*<br><br>Repurposing Host Targets for Influenza Therapy<br>*Kevin Harrod, University of Alabama, Birmingham, AL, USA*<br><br>HA Minibinders Proof-of-Concept in Mice and Ferrets<br>*Deborah Fuller, University of Washington, Seattle, WA, USA* |
| **11:00-11:30** | **Coffee Break** |
| **11:30-13:00** | **Session 3:** Oral Abstract Session 1- Preclinical Papers |
| **13:00-14:00** | **Sponsored Lunchtime Seminar - TBC** |
| **14:00-15:00** | **Session 4:** Symposium- Clinical Trial Design Issues<br><br>Clinical Pharmacology Considerations for Influenza and RSV Trials<br>*FDA Speaker*<br><br>Considerations of use of PROs in SARI and Hospitalized Influenza Studies<br>*FDA COA Speaker* |
| **15:00-15:30** | **Coffee Break** |
| **15:30-17:00** | **Session 5:** Oral Abstracts Session 2- Preclinical and Phase 1 Clinical Papers |
| **17:00-18:00** | **Welcome Buffet Reception** |

| **Wednesday 14 November** | |
|---|---|
| **08:30-10:35** | **Session 6:** Symposium - Updates on Clinical Trials<br><br>Evaluation of Anti-HA Stem Monoclonal Antibody FluA in Two Phase 2 Influenza Studies<br>*Melicent Peck, Genentech, South San Francisco, California, USA*<br><br>Baloxavir Marboxil, a Cap-Dependent Endonuclease Inhibitor - Development Updates<br>*Takeki Uehara, Shionogi & Co., Ltd, Osaka, Japan*<br><br>RSV Antiviral Treatment for HCT patients: Results from Recent Phase 2 Studies for Presatovir<br>*Michael Boeckh, University of Washington, Seattle, WA, USA*<br><br>Overview of RSV and Influenza Programmes<br>*James Witek, Janssen Research and Development, Titusville, New Jersey, USA*<br><br>Randomized Phase 2 Study Evaluating Nitazoxanide Versus Placebo in Hospitalized Subjects with Severe Acute Respiratory Illness<br>*John Beigel, NIAID, Bethesda, MD, USA* |
| **10:35-11:00** | **Coffee Break** |
| **11:00-13:00** | **Session 7:** Symposium- Clinical Trial and Regulatory Issues<br><br>FDA Considerations for Influenza Drug Development<br><br>○ Trial Designs for Serious Influenza<br>○ Therapeutic Combinations (Antivirals, Adjunctive Therapies)<br>○ Pediatric Considerations<br>*FDA Speaker*<br><br>Statistical Considerations/Endpoints<br>*LaRee Tracy, FDA, Silver Spring, MD, USA*<br><br>EMA Perspective<br>*Dr Radu Botgros, EMA, London, UK*<br><br>Investigator Perspective (Influenza)<br>*Michael Ison, Northwestern University, Chicago, Illinois, USA*<br><br>Discussion on RSV - FDA Guidance for Industry and Trial Designs/*Endpoint*<br>*FDA Speaker*<br><br>Investigator Perspective (RSV)<br>*John DeVincenzo, University of Tennessee, Memphis, Tennessee, USA* |
| **13:00-14:00** | **Sponsored Lunchtime Seminar - TBC** |
| **14:00-15:00** | **Session 8:** Roundtable Discussion- Clinical Trial and Regulatory Issues<br>*Academic, Regulatory, and Industry representatives* |
| **15:00-15:30** | **Coffee Break** |
| **15:30-17:00** | **Session 9:** Oral Abstract Session 3- Clinical Papers (Including Disease Pathogenesis, Biomarkers, Diagnostics) |

| | |
|---|---|
| **17:00-18:00** | **Poster Session** |
| **Thursday 15 November** | |
| **08:30-10:00** | **Session 10:** Oral Abstract Session 4- Clinical Trial Papers |
| **10:00-10:30** | **Coffee Break** |
| **10:30-12:30** | **Session 11:** Hot Topics and Late-Breakers<br><br>Antiviral Resistance Monitoring Strategies<br>*Aeron Hurt, WHO Collaborating Centre, Melbourne, Australia*<br><br>Novel Coronaviruses<br>*Ralph Baric, University of North Carolina, Chapel Hill, NC, USA*<br><br>Adjunctive Therapies<br>*Nelson Lee, University of Alberta, Edmonton, Canada* |
| **12:30-13:00** | Summary and Close of Conference |
| | **Lunch and Depart** |